- Home
- IGT vs FOLD Comparison
IGT vs FOLD Comparison
Compare IGT & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGT
- FOLD
- Stock Information
- Founded
- IGT 2014
- FOLD 2002
- Country
- IGT United Kingdom
- FOLD United States
- Employees
- IGT N/A
- FOLD N/A
- Industry
- IGT Services-Misc. Amusement & Recreation
- FOLD Biotechnology: Pharmaceutical Preparations
- Sector
- IGT Consumer Discretionary
- FOLD Health Care
- Exchange
- IGT Nasdaq
- FOLD Nasdaq
- Market Cap
- IGT 3.2B
- FOLD 2.9B
- IPO Year
- IGT N/A
- FOLD 2007
- Fundamental
- Price
- IGT $15.69
- FOLD $5.77
- Analyst Decision
- IGT Strong Buy
- FOLD Buy
- Analyst Count
- IGT 4
- FOLD 10
- Target Price
- IGT $23.25
- FOLD $16.22
- AVG Volume (30 Days)
- IGT 1.8M
- FOLD 5.4M
- Earning Date
- IGT 07-29-2025
- FOLD 08-07-2025
- Dividend Yield
- IGT 5.07%
- FOLD N/A
- EPS Growth
- IGT 44.55
- FOLD N/A
- EPS
- IGT 1.62
- FOLD N/A
- Revenue
- IGT $2,434,000,000.00
- FOLD $543,141,000.00
- Revenue This Year
- IGT $2.11
- FOLD $19.84
- Revenue Next Year
- IGT $1.40
- FOLD $23.18
- P/E Ratio
- IGT $9.71
- FOLD N/A
- Revenue Growth
- IGT 14.38
- FOLD 28.25
- 52 Week Low
- IGT $13.81
- FOLD $5.51
- 52 Week High
- IGT $24.13
- FOLD $12.65
- Technical
- Relative Strength Index (RSI)
- IGT 53.07
- FOLD 36.57
- Support Level
- IGT $14.80
- FOLD $5.51
- Resistance Level
- IGT $15.72
- FOLD $5.82
- Average True Range (ATR)
- IGT 0.36
- FOLD 0.19
- MACD
- IGT 0.13
- FOLD -0.01
- Stochastic Oscillator
- IGT 82.79
- FOLD 25.00
About IGT International Game Technology
International Game Technology PLC is a gaming company that delivers entertaining and responsible gaming experiences for players across all channels. The company operates into single segment namely Gaming & Digital. Geographically, it derives a majority of revenue from the United States. The company also has its presence in Italy, Rest of Europe and Other countries.
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.